| GTO ID | GTC2229 |
| Trial ID |
NCT04153149
|
| Disease |
Transthyretin Amyloidosis
|
Cardiomyopathy
|
| Altered gene | TTR |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | ALN-TTRSC02|AMVUTTRA|Vutrisiran |
| Location approved | US, EU, UK |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) |
| Year | 2019 |
| Country | Argentina|Australia|Austria|Belgium|Canada|Croatia|Czechia|Denmark|France|Germany|Hungary|Ireland|Israel|Japan|Korea, Republic of|Latvia|Lithuania|Netherlands|Norway|Peru|Poland|Portugal|Spain|Sweden|United Kingdom|United States |
| Company sponsor | Alnylam Pharmaceuticals |
| Other ID(s) | ALN-TTRSC02-003|2019-003153-28|2023-508366-15 |